Given the need for more efficacious treatments in OCD, and given emergent findings on the role of the glutamatergic system in this disorder, there is a need for additional pharmacotherapy trials on glutamatergic agents in OCD. Possible research designs for such trials might include stand-alone approaches, pharmacotherapy augmentation, or psychotherapy augmentation.
Naomi Fineberg, Eric Hollander, Stefano Pallanti, Susanne Walitza, Edna Grünblatt, Bernardo Dell’Osso, Umberto Albert, Daniel Geller, Vlasios Brakoulias, Y.C. Janardhan Reddy, Shyam Sundar Arumugham, Roseli Gedanke Shavitt, Lynne M. Drummond, Benedetta Grancini, Vera De Carlo, Eduardo Cinosi, Samuel R. Chamberlain, Konstantinos Ioannidis, Carolyn I. Rodríguez, Kabir Garg, David Castle, Michael Van Ameringen, Dan Joseph Stein, Lior Carmi, Joseph Zohar, José M. Menchón
Discussion(0)
No comments yet. Be the first to comment.